U.S. Vaccine Names

At a glance

This tables includes names and basic information for vaccines available in the U.S.

U.S. Vaccines: Table 1

(For Combination Vaccines, See Table 2)

Table 1: Vaccine Names, Abbreviations, Trade Names, and Manufacturers
Vaccine Trade Name Abbreviation Manufacturer Route Doses in Routine Series Approved Ages Comments
Adenovirus Adenovirus
Type 4 & Type 7		 Barr Labs Inc. Oral
(2 Tablets)		 1 17-50 years Live: Approved for military populations
Anthrax BioThrax® AVA Emergent BioSolutions IM 3 18-65 years Inactivated, Adj.
Cholera Vaxchora® PaxVax Oral (Liquid) 1 18-64 years Live Attenuated
COVID-19 Comirnaty® 1vCOV-mRNA Pfizer IM 2 ≥12 years mRNA
SPIKEVAX® 1vCOV-mRNA ModernaTx IM 2 ≥18 years mRNA
Dengue Dengvaxia® DEN4CYD Sanofi SC 3 9-16 years Live Recombinant
DTaP Daptacel® DTaP Sanofi IM 5 6 weeks-6 years Inactivated, Adj.
Infanrix® DTaP GlaxoSmithKline IM 5 6 weeks-6 years Inactivated, Adj.
DT Generic DT Sanofi IM 5 6 weeks-6 years Inactivated, Adj.: Use when pertussis is contraindicated
Haemophilus influenzae type b (Hib) ActHIB® Hib (PRP-T) Sanofi IM 4 2 months-5 years Inactivated, Adj.
(Tetanus toxoid conjugate)
Hiberix® Hib (PRP-T) GlaxoSmithKline IM 4 6 weeks-4 years Inactivated, Adj.
(Tetanus toxoid conjugate)
PedvaxHIB® Hib (PRP-OMP) Merck IM 3 2-71 months Inactivated, Adj.
(Meningococcal conjugate)
Hepatitis A Havrix® HepA GlaxoSmithKline IM 2 Pediatric:
12 months-18 years
Adult: ≥19 years		 Inactivated, Adj.
Vaqta® HepA Merck IM 2 Pediatric:
12 months-18 years
Adult: ≥19 years		 Inactivated, Adj.
Hepatitis B Engerix-B® HepB GlaxoSmithKline IM 3 Pediatric:
Birth-19 years
Adult: ≥20 years		 Recombinant, Adj.
Recombivax HB® HepB Merck IM 3 Pediatric:
Birth-19 years
Adult: ≥20 years		 Recombinant, Adj.
Heplisav-B® HepB Dynavax Technologies IM 2 ≥18 years Recombinant, Adj.
Herpes Zoster (Shingles) Shingrix® RZV GlaxoSmithKline IM 2 ≥50 years Recombinant, Adj.
Human Papillomavirus
(HPV)		 Gardasil® 9 9vHPV Merck IM 2 or 3 9-45 years Recombinant, Adj.
ACIP recommends 9-26 years
Influenza Afluria® IIV3
IIV4		 Seqirus IM 1 or 2 ≥5 years Inactivated
Fluad® IIV3 Seqirus IM 1 ≥65 years Inactivated, Adj.
Fluarix® IIV4 GlaxoSmithKline IM 1 or 2 ≥6 months Inactivated
Flublok® RIV4 Sanofi IM 1 ≥18 years Recombinant, Egg-Free
Flucelvax® ccIIV4 Seqirus IM 1 or 2 ≥4 years Cell-Culture
FluLaval® IIV4 GlaxoSmithKline IM 1 or 2 ≥6 months Inactivated
FluMist® LAIV4 Medimmune Intranasal 1 or 2 2-49 years Live Attenuated
Fluzone® IIV3
IIV4		 Sanofi IM 1 or 2 ≥6 months Inactivated
Fluzone®
High-Dose		 IIV3 Sanofi IM 1 ≥65 years Inactivated
Japanese encephalitis Ixiaro® JE Valneva IM 2 ≥2 months Inactivated, Adj.
Measles, Mumps, Rubella M-M-R® II MMR Merck SC 2 ≥12 months Live Attenuated
Meningococcal Menactra® MCV4
MenACWY-D		 Sanofi IM 2 9 months-55 years Inactivated (Diphtheria toxoid conjugate)
Menveo® MCV4
MenACWY-CRM		 GlaxoSmithKline IM 2 2 months-55 years Inactivated
(CRM197 conjugate)
Trumenba® MenB-FHbp Pfizer IM 2 or 3 10-25 years Recombinant, Adj.
Bexsero® MenB-4C GlaxoSmithKline IM 2 10-25 years Recombinant, Adj.
Pneumococcal Pneumovax® 23 PPSV23 Merck IM or SC 1 ≥2 years Inactivated Polysaccharide
Prevnar 13® PCV13 Pfizer IM 4 ≥6 weeks Inactivated, Adj.
(CRM197 conjugate)
Polio Ipol® IPV Sanofi IM or SC 4 ≥6 weeks Inactivated
Rabies Imovax® Rabies Sanofi IM 3 (pre-exposure)
5 (post-exposure)		 All ages Inactivated
RabAvert® GlaxoSmithKline IM 3 (pre-exposure)
5 (post-exposure)		 All ages Inactivated
Rotavirus RotaTeq® RV5 Merck Oral (Liquid) 3 6-32 weeks Live, Pentavalent
Rotarix® RV1 GlaxoSmithKline Oral (Liquid) 2 6-24 weeks Live, Monovalent
Tetanus,
(reduced) Diphtheria		 Tenivac® Td Sanofi IM 1 (Every 10 years) ≥7 years Inactivated, Adj.
(Generic) Td Massachusetts Biological Labs IM 1 (Every 10 years) ≥7 years Inactivated, Adj.
Tetanus, (reduced) Diphtheria,
(reduced) Pertussis		 Boostrix® Tdap GlaxoSmithKline IM 1 ≥10 years Inactivated, Adj.
Adacel® Tdap Sanofi IM 1 10-64 years Inactivated, Adj.
Typhoid Typhim Vi® Sanofi IM 1 ≥2 years Inactivated, Polysaccharide
Vivotif® PaxVax Oral (Capsules) 4 ≥6 years Live Attenuated
Varicella Varivax® VAR Merck SC 2 ≥12 months Live Attenuated
Vaccinia (Smallpox) ACAM2000® Sanofi Percutaneous 1 All ages Live Attenuated
Yellow Fever YF-Vax® YF Sanofi SC 1 ≥9 months Live Attenuated

U.S. Vaccines: Table 2

(Combination Vaccines)

Table 2: Vaccine Names, Abbreviations, Trade Names, and Manufacturers, Combination Vaccines
Vaccine Trade Name Abbreviation Manufacturer Route Doses in Routine Series Approved Ages Comments
DTaP, Polio Kinrix® DTaP-IPV GlaxoSmithKline IM 1 4-6 years Inactivated, Adj.: Approved as 5th DTaP and 4th IPV.
Quadracel® DTaP-IPV Sanofi IM 1 4-6 years Inactivated, Adj.: Approved as 5th DTaP and 4th IPV.
DTaP, Hepatitis B, Polio Pediarix® DTaP-HepB-IPV GlaxoSmithKline IM 3 6 weeks-6 years Inactivated, Adj.: Approved for 2, 4, 6 month doses.
DTaP, Polio, Haemophilus influenzae type b Pentacel® DTaP-IPV/Hib Sanofi IM 4 6 weeks-4 years Inactivated, Adj.: Approved for 2, 4, 6, 15-18 month doses.
DTaP, Polio, Haemophilus influenzae type b, Hepatitis B Vaxelis® DTap-IPV-Hib-HepB Sanofi IM 3 6 weeks-4 years Recombinant
Hepatitis A, Hepatitis B Twinrix® HepA-HepB GlaxoSmithKline IM 3 ≥18 years Inactivated/Recombinant, Adj.
Pediatric HepA + Adult HepB
Measles, Mumps, Rubella, Varicella ProQuad® MMRV Merck SC 2 12 months-
12 years		 Live Attenuated

Notes

  • The abbreviations on this table (Column 3) were standardized jointly by staff of the Centers for Disease Control and Prevention, ACIP Work Groups, the editor of the Morbidity and Mortality Weekly Report (MMWR), the editor of Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book), ACIP members, and liaison organizations to the ACIP. These abbreviations are intended to provide a uniform approach to vaccine references used in ACIP Recommendations and Policy Notes published in the MMWR, the Pink Book, and the American Academy of Pediatrics Red Book, and in the U.S. immunization schedules for children, adolescents, and adults. In descriptions of combination vaccines, a hyphen (-) indicates products in which the active components are supplied in their final (combined) form by the manufacturer; a slash ( / ) indicates products in which active components must be mixed by the user.
  • "Doses in a Routine Series" (Column 6) reflects doses administered to a healthy patient at the recommended ages. It doesn't necessarily reflect schedules for patients with health conditions or other high-risk factors, alternative schedules, catch-up schedules, or booster doses not part of an initial series. For some combination vaccines, this column represents the routine number of doses for that product, and not necessarily the total number of doses in a complete series for the components. (For example, Kinrix® or Quadracel® may be used for only 1 dose of multi-dose DTaP and IPV series.)
  • "Adj." in the "Comments" column indicates that the vaccine contains an adjuvant.
  • A hyphen in an age range means "through" (i.e., "6 weeks-6 years" means 6 weeks through 6 years [to the 7th birthday]).

Additional Resources

Vaccines Licensed for Use in the United States (FDA)

Print
Content Source:
National Center for Immunization and Respiratory Diseases